Replies to post #35530 on Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

MP, I have no idea what the value of our HER2 construct is. I have read before that breast cancer trials in general take longer than other cancer types and that the market for breast cancer and HER2 is extremely competitive, so I think it's a big stretch to assume if we eventually get an approval for breast cancer that a year or two later 70% of all new breast cancer cases will be given the ADXS treatment.